Percheron Therapeutics Limited
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael Baker
- Full Time Employees
- 8
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- L30, Collins Place Melbourne VIC Australia 3000
- IPO Date
- Nov 28, 2001
- Website
- percherontx.com
- Similar Companies
- Business
- Percheron Therapeutics Limited (ASX:PER) is an Australian biotechnology company focused on the research, development and commercialization of novel antisense oligonucleotide therapies targeting rare diseases and oncology indications. Founded in 2000 and headquartered in Melbourne, Victoria, the company leverages Ionis Pharmaceuticals' proprietary drug discovery platform to design inhibitors that bind to specific mRNA sequences, preventing protein production implicated in disease pathology; its lead product candidates include avicursen (ATL1102), an antisense inhibitor of the CD49d receptor in Phase II development for Duchenne muscular dystrophy, limb-girdle muscular dystrophy and multiple sclerosis, and atesidorsen (ATL1103), a growth hormone receptor antagonist that has completed Phase II trials for acromegaly and is under evaluation for other growth hormone-related disorders. The company operates primarily in Australia with global development ambitions, targeting unmet needs in rare pediatric diseases that have garnered US FDA orphan drug and rare pediatric designations for key programs. In December 2023, the company rebranded from Antisense Therapeutics Limited to Percheron Therapeutics Limited to reflect its expanded pipeline focus. Following a negative Phase IIb outcome for its lead program in December 2024, Percheron accelerated partnering discussions in early 2025, receiving initial proposals by February and actively pursuing strategic alliances; in June 2025, it in-licensed HMBD-002, a monoclonal antibody from Singapore-based Hummingbird Bioscience, for solid tumor applications, marking a diversification into antibody therapeutics alongside its core antisense platform. As of September 2025, the company reported A$5.7 million in cash reserves after milestone payments, supporting ongoing pipeline advancement and business development amid a lean operation with approximately eight employees.
Company News
Edison Issues Report on Percheron Therapeutics (PER)
Percheron Therapeutics receives $700,000 R&D rebate to support HMBD-002 cancer program
Percheron Therapeutics Phase II progress highlighted by Edison with 5.5-cent valuation
Provaris Energy advances hydrogen and CO₂ shipping technologies during June quarter
American Rare Earths advances Halleck Creek feasibility and pilot plant plans in pivotal June quarter
archTIS caps record FY2026 quarter with ARR surge and defence momentum
St George Mining accelerates Araxá development after strong June quarter
Noble Helium strengthens balance sheet and advances Kinambo drilling during June quarter
Percheron Therapeutics targets clinical return for HMBD-002 after productive June quarter
Altech Batteries sharpens CERENERGY focus after securing grant extension in June quarter
FTSE 100 Live: London stocks flat as miners and oilers fall, SpaceX wobbles
AIC Mines high-grade Jolly results support Jericho copper mine start-up
International Graphite targets European graphite supply chain with Alkeemia JV in Italy
St George Mining secures A$60 million to fast-track rare earths-niobium project in Brazil
Small Cap Watch: St George Mining raises A$60m and graphite, biotech stocks advance key milestones
Percheron Therapeutics clears HMBD-002 manufacturing milestone ahead of new cancer drug trial
Percheron presents ASCO data supporting HMBD-002's potential in hard-to-treat breast cancer
Small cap Watch: Biotech, gold explorers and consumer brands deliver key updates
Percheron Therapeutics secures proposed WHO drug name for HMBD-002 cancer therapy
Imugene strengthens board with biotech and pharma appointments